Contributions of GABAAReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
When benzodiazepines (BZs) supplanted barbiturates as a favored, safer treatment for anxiety and sleep disorders in the 1960s, the abuse liability and dependence potential of these drugs were little understood. Widespread recognition of the difficulty of stopping use of chronically taken BZs emerged through the popular press in the late 1970s, which resulted in reluctance to prescribe these otherwise clinically useful compounds. Evolution of the understanding of the biochemical basis for BZ effects in the 1980s and 1990s, coupled with regulatory emphasis on collection of data used in legal scheduling decisions, made possible a targeted search for drugs that would provide effective treatment for anxiety disorders in the absence of abuse liability or dependence potential. Compounds that have selective efficacy at subtypes of the γ-aminobutyric acid type A receptor, are active in preclinical anxiolytic screens, but negative in preclinical studies of behavior relevant to evaluation of abuse liability appear to be one promising means for achieving this end.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using self-administration studies, it was shown that efficacy at α 1-containing GABAA subtypes significantly contributed to the reinforcing effects and withdrawal symptoms of benzodiazepines [8, 28, 29].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [28]
Citations
Cites
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
Benzodiazepine receptors in rat brain
SQUIRES, R. F., & BRAESTRUP, C. (1977) · Nature · doi:10.1038/266732a0 · Cited by 1,449
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
The Pharmacological Basis of Therapeutics
Utz, J. P., Goodman, L. S., & Gilman, A. (1966) · Mycologia · doi:10.2307/3757079 · Cited by 492
Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors
Squires, R. F., Benson, D. I., Braestrup, C., Coupet, J., Klepner, C. A., Myers, V., & Beer, B. (1979) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(79)90341-1 · Cited by 408
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340 · cited 1×
“ABUSE LIABILITY ASSESSMENT OF COMPOUNDS SLATED FOR CLINICAL USE The abuse liability of barbiturates and BZs primarily became apparent in the context of their clinical use rather than being predicted by preclinical testing.(20) Governmental regulations in developed countries now require that data that will permit an ab…”
BackgroundAbuse liability of benzodiazepines.
Woods, J. H., Katz, J. L., & Winger, G. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06658-x · Cited by 315
Zolpidem: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential
Langtry, H. D., & Benfield, P. (1990) · Drugs · doi:10.2165/00003495-199040020-00008 · Cited by 297
Principles of drug abuse liability assessment in laboratory animals
Ator, N. A., & Griffiths, R. R. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00099-1 · Cited by 249
Self-citationOverview of Diagnosis and Drug Treatments of Anxiety Disorders
Nutt, D. J. (2005) · CNS Spectrums · doi:10.1017/s1092852900009901 · Cited by 211 · cited 1×
“The impact of these events reverberates to the present day in restrictive laws, litigious former patients, and a general reluctance to prescribe a BZ.(7)'(10) This outcome likely could have been avoided had physicians and patients been fully aware of the possibility of a withdrawal syndrome upon discontinuation and of…”
Background
Research works printed but not linked: 6
- Lader, 1987, Benzodiazepine dependence. ISI Atlas of Science: Pharmacology, 299
- 10.1037/1064-1297.8.3.294 · doi:10.1037/1064-1297.8.3.294
- 2001, Thirty-Second Report
- Rush, 2001, Animal Research and Human Health, 101
- Yanagita, 1983, Problems of Drug Dependence, 1982; Proceedings of the 44th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph Series 43, 164
- Ator, Drug Alcohol Depend
Cited by
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
“…at a1 GABAA receptors, such as L-838 417 (McKernan et al., 2000) or TPA023, a partial agonist at a2 and a3 receptors (Atack, 2009), provided anxiolytic activity devoid of sedation and with no or low dependence liability compared to classical benzodiazepines (Ator, 2005; Licata and Rowlett, 2008).”
BackgroundReversal of pathological pain through specific spinal GABAA receptor subtypes
Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008) · Nature · doi:10.1038/nature06493 · Cited by 438
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
“Some experimental data and clinical reports suggest that zolpidem may have a lower risk of dependence, abuse, and misuse than other typical benzodiazepines [75-81].”
Background
Metadata
- Authors
- Ator, N. A.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Ator, Nancy A.
- ORCID
- Ator, Nancy A.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2005-01
- Volume
- 10
- Issue
- 1
- Pages
- 31-39
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2404476850
- Cited by
- 59
- References
- 61
- Citations by year
- 2026: 2 · 2024: 1 · 2022: 1 · 2021: 2 · 2020: 3 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 4
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01-DA-04133, R01DA004133)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- GABAA receptor subtypes, benzodiazepines, abuse liability, anxiolytics, sleep disorders, anxiety disorders, drug scheduling, barbiturates
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Binding, Competitive, Humans, Receptors, GABA-A, Self Administration, Sleep Wake Disorders, Liability, Legal, GABA Modulators, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contributions of GABAAReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders. https://app.cochat.ai/papers/10.1017/s1092852900009883
- The paper
- Ator, N. A. (2005). Contributions of GABAAReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900009883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.